Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.

• Autores: V. Narayanan, J.A Gutman, D.A Pollyea, Antonio Jimeno
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 49, Nº. 7, 2013, págs. 447-456
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Omacetaxine mepesuccinate is a protein synthesis inhibitor that causes apoptosis of chronic myeloid leukemia cells without binding to the BCR-ABL tyrosine kinase that is implicated in the pathogenesis of this disease. It has been approved for the treatment of chronic myeloid leukemia in patients with resistance to two or more tyrosine kinase inhibitors and is emerging as an important agent in countering the highly resistant T315I mutation. This review will focus on the preclinical pharmacology, pharmacokinetics and clinical utility of omacetaxine mepesuccinate in the current milieu of tyrosine kinase inhibitor-dominant therapy of chronic myeloid leukemia.